A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

Phase 1/2 Recruiting 150 enrolled Rhythm Pharmaceuticals, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and PK of RM-718 in healthy subjects with obesity and in patients with MC4R Pathway Impairment

Timeline

Start: 2024-03-05
Primary completion: 2027-11-01
Completion: 2028-11-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RM-718	Unknown	—	Subcutaneous

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

Summary

Timeline

Drugs

Indications